Hypoxia-mimetic agents inhibit proliferation and alter the morphology of human umbilical cord-derived mesenchymal stem cells
- Hui-Lan Zeng†1,
- Qi Zhong†1, 2,
- Yong-Liang Qin1,
- Qian-Qian Bu1,
- Xin-Ai Han1, 3,
- Hai-Tao Jia4 and
- Hong-Wei Liu5Email author
© Zeng et al; licensee BioMed Central Ltd. 2011
Received: 17 February 2011
Accepted: 9 August 2011
Published: 9 August 2011
The therapeutic efficacy of human mesenchymal stem cells (hMSCs) for the treatment of hypoxic-ischemic diseases is closely related to level of hypoxia in the damaged tissues. To elucidate the potential therapeutic applications and limitations of hMSCs derived from human umbilical cords, the effects of hypoxia on the morphology and proliferation of hMSCs were analyzed.
After treatment with DFO and CoCl2, hMSCs were elongated, and adjacent cells were no longer in close contact. In addition, vacuole-like structures were observed within the cytoplasm; the rough endoplasmic reticulum expanded, and expanded ridges were observed in mitochondria. In addition, DFO and CoCl2 treatments for 48 h significantly inhibited hMSCs proliferation in a concentration-dependent manner (P < 0.05). This treatment also increased the number of cells in G0/G1 phase and decreased those in G2/S/M phase.
The hypoxia-mimetic agents, DFO and CoCl2, alter umbilical cord-derived hMSCs morphology and inhibit their proliferation through influencing the cell cycle.
Human mesenchymal stem cells (hMSCs) were first identified by Friedenstein et al.  in 1974. As non-hematopoetic, multipotent bone marrow stem cells, hMSCs are more primitive and embryonic-like cells with the potential to differentiate into lineage-committed progenitors and mature cells, such as osteoblasts and fibroblasts . However, bone marrow is not the exclusive source of MSCs; they have been isolated from virtually all post-natal and extra-embryonic tissues, including amniotic membrane, placenta, umbilical cord, and umbilical cord blood [3–5]. In recent years, hMSCs have been commonly used in tissue engineering, cell replacement therapy, gene therapy, and body organ/fluid transplantation.
Oxygen is a potent signaling molecule, affecting the fundamental characteristics of various types of cells. Specifically, reduced oxygen levels or hypoxia influences blood-brain barrier permeability through influencing endothelial cell junctional complexes . Furthermore, hypoxia induced proliferation of hematopoietic bone marrow stem cells . In addition, hypoxia-inducible factor-1 alpha (HIF-1α), a critical transcription factor in the mammalian oxygen-sensing pathway, is activated in response to hypoxia, altering tumor xenograft gene expression, growth, and angiogenesis  possibly through membrane type 1 metalloprotease . MSCs exposed to hypoxic conditions exhibit greater colony-forming potential , faster and prolonged proliferation [11–13], and greater chemotaxis . Exposure of MSCs to hypoxia also prolonged their differentiation .
Hypoxia is often induced by decreasing oxygen concentrations [15, 16]. In addition, the hypoxia-mimetic agents, cobalt chloride (CoCl2) and desferrioxamine (DFO), an iron chelator, artificially induce hypoxia through blocking the degradation of HIF-1α [17, 18]. The effects of hypoxia-mimetic agents are comparable to those resulting from reduced atmospheric oxygen levels [17, 19].
Analysis of stem cell proliferation and differentiation is often carried out in 20% O2, which is much greater than that found in vivo; arterial oxygen concentration is approximately 12% while bone marrow ranges from 1 to 7% . Therefore, the effects of DFO and CoCl2 on human umbilical cord-isolated hMSCs were assessed. The ultrastructure of hMSCs in response to hypoxia was analyzed using atomic force microscopy (AFM) and transmission electron microscopy (TEM). In addition, the effects of hypoxia mimetics on hMSCs proliferation were analyzed. Determining the effects of hypoxia on hMSCs morphology and proliferation may contribute to identifying the mechanisms by which hypoxia influences hMSCs chemotaxis and migration as well as characterize their therapeutic application for hypoxia-related disease.
Morphological and immunophenotypic characterization of umbilical cord-derived hMSCs
Effects of DFO and CoCl2 on hMSCs proliferation
Effects of hypoxia mimetics on hMSCs cell cycle
Effects of DFO and CoCl2 of different concentrations on cell cycle distribution of hMSCs detected by flow cytometry with PI staining
80.03 ± 4.28
82.67 ± 3.25
86.41 ± 3.13
81.96 ± 2.21
85.87 ± 2.93
1.52 ± 0.57
1.35 ± 1.29
1.30 ± 1.32
1.37 ± 0.29
1.32 ± 0.74
18.45 ± 4.10
15.98 ± 4.21
12.29 ± 1.95
16.67 ± 2.13
12.81 ± 2.87
Effects of hypoxia mimetics on hMSCs morphology
hMSCs were exposed to factors inducing adipogenic and osteogenic differentiation for 21 days in normoxic conditions after which the morphology was assessed. The nuclei of adipogenic-induced hMSCs moved to peripheral area while the cell membranes became more granular, which was suggestive of the S phase of the cell cylce (Figures 3C and 3D). Osteogenic-induced hMSCs appeared more elevated, square and rigid than undifferentiated cells (Figures 3G and 3H).
Human umbilical cords represent a promising source of hMSCs, which can be conveniently isolated and induce low immunogenicity. In addition, as compared to other stem cell sources these present relatively few ethical issues. The hMSCs isolated from umbilical cords were positive for CD44, CD29 and CD105, and negative for CD106, CD40, CD34, CD45 and HLA-DR surface antigens, confirming their identity as MSCs . In addition, the isolated hMSCs were able to differentiate into adipogenic and osteogenic cells under specific culture conditions.
The intracellular cytoskeleton responds to external mechanical stimuli . Tapping mode AFM was used to observe the surface structures. The position of the adipogenic cell nuclei and their granular quality of the membranes is suggestive of early S phase of the cell cycle. Osteogenic-induced hMSCs appeared larger, squarer and more rigid as compared to undifferentiated cells, which is consistent with that reported by Danti et al. . In addition, they were easily distinguishable from each other as the differentiation process prevented their proliferation, which also correlates with Danti et al .
Differentiation of MSCs is also influenced by hypoxia. Qu et al.  reported that DFO increased the osteoblastic differentiation of bone morphogenetic protein-2-treated MSCs. Valorani et al.  and Ren et al.  observed that hypoxia (2 and 8%, respectively) increased the adipogenic differentiation potential of MSCs. These studies suggest that pre-culturing MSCs under hypoxic conditions prior to transplantation may enhance their efficacy.
As evidenced by clinical trials in hypoxic-ischemic diseases, MSCs-based therapy has potential value in tissue replacement and regeneration [26–28]. The effects of in vivo oxygen concentrations, which are much lower than common experimental conditions, on hMSCs were largely unknown. Therefore, hMSCs proliferation and morphology in response to hypoxia induced by DFO and CoCl2 was assessed. After treatment with DFO and CoCl2, hMSCs were more elongated, and gaps appeared between adjacent cells. Thus, DFO and CoCl2 may inhibit hMSCs growth by weakening cell-to-cell signaling. The reduction in cell-cell junctions may also mediate hMSCs migration induced by hypoxia (3% oxygen) . Further studies are necessary to determine the effects of DFO and CoCl2 treatment on the signaling pathways that govern hMSCs migration.
The influence of hypoxia on hMSCs ultrastructure was also explored by TEM. After treatment with DFO, hMSCs contained a large number of unidentifiable vacuoles that are early markers of apoptosis, which is consistent with Ren et al.  using 8% oxygen. In addition, the observed shrinkage, disintegration, and dissolution of the nucleus, along with chromatin condensation indicated early apoptosis. Consistent with the signs of apoptosis, we found that hMSCs proliferation decreased in a dose-dependent manner with increasing concentrations of CoCl2 and DFO. However, discrepant effects of physical hypoxia and hypoxia mimetics on MSCs proliferation indicate differences. For example, Ren et al.  reported that low oxygen levels (8%) promoted MSCs proliferation, whereas DFO (120 μM) and CoCl2 (100 μM) inhibited their growth. Lavrentieva et al.  reported that 1.5-5% oxygen levels increased the proliferative capacity of hMSCs. Whereas Qu et al.  found that DFO, ranging from 0 to 100 μM, inhibited cell growth in a dose-dependent manner. HIF-1α levels may differ under physically-induced hypoxia as opposed to CoCl2-induced hypoxia [12, 16] which may account for these differences; however, further analysis is required.
The effects of CoCl2 and DFO on hMSCs proliferation may be mediated by cell cycle changes. A larger percentage of DFO- and CoCl2-treated cells in the G0/G1 phase was observed, while the ratio of those in the G2/M/S phase decreased. Similar results were reported by Holzwarth et al. , who reported hMSCs accumulation in the G1 phase at 1% oxygen. Further studies are necessary to determine if the cell cycle effects of hypoxia mimetics can be recapitulated under low oxygen conditions.
There are several study limitations that warrant discussion. Firstly, the present study analyzed the effects of hypoxia mimics on hMSCs; however, the effects of physical hypoxia were not assessed. Further studies will be carried out to compare the effects of physical hypoxia and hypoxia mimetics on hMSCs morphology and growth. In addition, the effects of DFO and CoCl2 on hMSC HIF-1α levels were not analyzed. However, previous studies using the same concentrations of DFO and CoCl2 used in the present study have reported upregulation of HIF-1α expression [12, 32]. Furthermore, the present study did not analyze the influence of DFO and CoCl2 on MSCs differentiation. Although the effects of these agents on MSCs morphology is suggestive of greater self-renewal capacity as hMSCs broaden and flatten with differentiation , and differentiation was associated with changes in nuclear morphology [34, 35], determining their effects on MSCs differentiation will be the focus of future studies. Finally, the effects of hypoxia-induced morphological changes on MSCs function (e.g., cell migration, homing or immune regulatory effect) was not explored in the present study, but will be analyzed in future studies. Although the present study has its limitations, determining the ways in which MSCs respond to environments with lower than atmospheric oxygen concentrations, such as the blood, bone marrow, and cartilage, is crucial for their successful use regenerative medicine. The present study advances our understanding of the influences of hypoxia on MSCs morphology and proliferation.
We isolated and cultured hMSCs from umbilical cords. The proliferation of hMSCs was inhibited by DFO and CoCl2. The cell surface and ultrastructure was viewed with atomic force microscopy and transmission electron microscopy after DFO- and CoCl2-induced hypoxia, which is the first time this has been reported. These data will provide a better understanding of the potential therapeutic applications of hMSCs in hypoxic-ischemic disease.
Isolation and culture of hMSCs from umbilical cord and treatment with hypoxia-mimetic agents
hMSCs were obtained from the umbilical cords of healthy full-term infants born by cesarean section. Tissues were washed with phosphate buffered saline (PBS), cut into approximately 1 cm3 pieces, and digested with 0.2% type II collagenase (Gibco, USA) at 37°C for 5-6 h. After filtration and centrifugation, the cells were incubated in DMEM/F12 medium supplemented with 10% fetal bovine serum (FBS, Gibco, USA), 100 U/mL penicillin and 100 U/mL streptomycin. Cells were inoculated at density of 1 × 106 cells/mL in 25 cm2 culture flasks (Corning, NY) and maintained at 37°C in a humidified atmosphere containing 5% CO2. After 4-5 days, non-adherent cells were removed. The culture medium was replaced every 3 days, and adherent cells were cultured until they reached 80-90% confluence. Cells at passage 3-7 were used to analyze the effects of hypoxia-mimetic agents. Informed consent for the use of the umbilical cords was obtained from each mother prior to surgery. The study was approved by The Ethics Committee of the First Affiliated Hospital, Jinan University, Guangzhou, China.
DFO and CoCl2 were dissolved in ultrapure water and applied to the hMSCs cultures at concentrations of 10, 25, 50, and 100 μM for CoCl2 and 15, 30, 60, and 120 μM for DFO. Control groups consisted of cells grown in the absence of DFO and CoCl2.
Immunophenotype determination and cell cycle analysis
hMSCs were incubated with either phycoerythrin or FITC-conjugated antibodies specific for CD29, CD44, CD90, CD105, CD106, CD40, CD34, and CD45 (BD Biosciences, San Jose, CA). Mouse isotype control antibodies served as negative controls. Cells were stained with a single label and analyzed by flow cytometry using a BD FACSCalibur.
Cell cycle was analyzed through propidium iodide (PI)-staining. hMSCs (106 cells) in the third passage were fixed, permeabilized in 70% cold ethanol at 4°C for 24 h, and treated with 200 μg/mL RNase A for 30 min at 37°C. hMSCs were then incubated in 40 μg/mL PI for 5 min at room temperature, and placed on ice until analysis by flow cytometry.
Analysis of hMSCs differentiation
To evaluate hMSCs properties, adherent cells (in the third passage, at 80-90% confluence) were subjected to adipogenic and osteogenic differentiation in vitro, according to established protocols [36, 37]. For adipogenic differentiation, cells were incubated in DMEM/F12 media supplemented with 10% FBS, 100 U/mL penicillin, 100 U/mL streptomycin, 5 μg/mL insulin, 50 mM indomethacin, 1 μM dexamethasone, and 0.5 mM 3-isobutyl-1-methylxanthine. Adipogenic differentiation was confirmed on the 21st day by observing the intracellular accumulation of lipid-rich vacuoles stained with oil red O. For osteogenic differentiation, cells were incubated in DMEM/F12 media supplemented with 10% FBS, 100 U/mL penicillin, 100 U/mL streptomycin, 10 mM b-glycerol phosphate, 100 nM dexamethasone, and 50 μM ascorbate 2-phosphate for 21 days. Osteogenic differentiation was confirmed by the accumulation of mineralized calcium phosphate and assessed using the von Kossa staining method, which entails incubating the cells in 1% silver nitrate for 60 min under ultraviolet light followed by 3% sodium thiosulfate for 5 min at room temperature.
MTT proliferation assay
After treatment, cell growth media was replaced with 200 μL MTT solution (5 g/L in PBS) per well for 4 h after which it was replaced with 150 μL dimethyl sulphoxide. Quantification was then carried out using a microplate reader at 570 nm; a 630 nm filter was used as a reference.
Atomic force microscopy
hMSCs were cultured on glass coverslips in growth media alone (control group) or containing 120 μM DFO or 100 μM CoCl2. After the cells reached 70-80% confluence at 72 h, they were gently washed with PBS, fixed with 4% paraformaldehyde, washed with demineralized water, and air dried. Tapping-mode atomic force microscopy analysis (Autoprobe CP research, Thermomicroscopes, California, USA) was performed with silicon nitride tips (spring constant, 0.9 N/m) using a Park Scientific Instruments commercial instrument (MPP-31123). The scanning speed was 0.4-1HZ. The IP2.1 software (Thermomicroscopes Proscan Image Processing Software Version 2.1, California, USA) applied smoothing analysis to the resulting images.
Transmission electron microscopy
TEM was used to assess the morphological characteristics of hMSCs. hMSCs cultured for 72 h in media containing 120 μM DFO were immediately fixed at 4°C with 2.5% glutaraldehyde, post-fixed in osmium, and routinely processed for TEM assessment (PHILIP5 TECNAI 10, HOLLAND). Cells cultured in complete medium alone were used as a control group.
Statistical analyses were performed using SPSS 15.0 statistics software (SPSS Inc, Chicago, IL, USA). Data were expressed as mean ± standard deviation (SD). One-way ANOVA test with a post-hoc Bonferoni comparison was performed to compare the data among concentrations. Furthermore, a repeated ANOVA test for repeated cell growth was performed to compare the data among concentrations. Finally, a generalized linear model analysis was applied to show changes in data over time. All P-values < 0.05 were considered significant.
This work was supported by grants from the the National Natural Science Foundation of China (Grant No. 30973127) and the Natural Science Foundation of Guangdong Province, China (Grant No.06300580).
- Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV: Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues, Cloning in vitro and retransplantation in vivo. Transplantation. 1974, 17: 331-40. 10.1097/00007890-197404000-00001.View ArticlePubMed
- Majore I, Moretti P, Hass R, Kasper C: Identification of subpopulations in mesenchymal stem cell-like cultures from human umbilical cord. Cell Communication and Signaling. 2009, 7: 1-8. 10.1186/1478-811X-7-1.View Article
- Alviano F, Fossati V, Marchionni C, Arpinati M, Bonsi L, Franchina M, Lanzoni G, Cantoni S, Cavallini C, Bianchi F, Tazzari PL, Pasquinelli G, Foroni L, Ventura C, Grossi A, Bagnara GP: Term Amniotic membrane is a high throughput source for multipotent Mesenchymal Stem Cells with the ability to differentiate into endothelial cells in vitro. BMC Dev Biol. 2007, 7: 1-14. 10.1186/1471-213X-7-1.View Article
- Fukuchi Y, Nakajima H, Sugiyama D, Hirose I, Kitamura T, Tsuji K: Human placenta-derived cells have mesenchymal stem/progenitor cell potential. Stem Cells. 2004, 22: 649-58. 10.1634/stemcells.22-5-649.View ArticlePubMed
- Secco M, Zucconi E, Vieira NM, Fogaça LL, Cerqueira A, Carvalho MD, Jazedje T, Okamoto OK, Muotri AR, Zatz M: Multipotent Stem Cells from Umbilical Cord: Cord Is Richer than Blood. Stem Cells. 2008, 26: 146-50. 10.1634/stemcells.2007-0381.View ArticlePubMed
- Fischer S, Wiesnet M, Marti HH, Renz D, Schaper W: Simultaneous activation of several second messengers in hypoxia-induced hyperpermeability of brain derived endothelial cells. J Cell Physiol. 2004, 198: 359-69. 10.1002/jcp.10417.View ArticlePubMed
- Toya RE, Barrett JV, Davis ML: Hypoxia induced proliferation of hematopoietic stem-cells in bone-marrow of mice. Radiat Res. 1976, 67: 591-
- Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, Ratcliffe PJ: Hypoxia inducible factor-1 modulates gene expression in solid tumors andinfluences both angiogenesis and tumor growth. Proc Natl Acad Sci USA. 1997, 94: 8104-9. 10.1073/pnas.94.15.8104.PubMed CentralView ArticlePubMed
- Annabi B, Lee YT, Turcotte S, Naud E, Desrosiers RR, Champagne M, Eliopoulos N, Galipeau J, Béliveau R: Hypoxia promotes murine bone-marrow-derived stromal cell migration and tube formation. Stem Cells. 2003, 21: 337-47. 10.1634/stemcells.21-3-337.View ArticlePubMed
- Grayson WL, Zhao F, Izadpanah R, Bunnell B, Ma T: Effects of hypoxia on human mesenchymal stem cell expansion and plasticity in 3D constructs. J Cell Physiol. 2006, 207: 331-9. 10.1002/jcp.20571.View ArticlePubMed
- Martin-Rendon E, Hale SJ, Ryan D, Baban D, Forde SP, Roubelakis M, Sweeney D, Moukayed M, Harris AL, Davies K, Watt SM: Transcriptional profiling of human cord blood CD133(t) and cultured bone marrow mesenchymal stem cells in response to hypoxia. Stem Cells. 2007, 25: 1003-12. 10.1634/stemcells.2006-0398.View ArticlePubMed
- Ren H, Cao Y, Zhao Q, Li J, Zhou C, Liao L, Jia M, Zhao Q, Cai H, Han ZC, Yang R, Chen G, Zhao RC: Proliferation and differentiation of bone marrow stromal cells under hypoxic conditions. Biochem Biophys Res Commun. 2006, 347: 12-21. 10.1016/j.bbrc.2006.05.169.View ArticlePubMed
- Fehrer C, Brunauer R, Laschober G, Unterluggauer H, Reitinger S, Kloss F, Gülly C, Gassner R, Lepperdinger G: Reduced oxygen tension attenuates differentiation capacity of human mesenchymal stem cells and prolongs their lifespan. Aging Cell. 2007, 6: 745-57. 10.1111/j.1474-9726.2007.00336.x.View ArticlePubMed
- D'Ippolito G, Diabira S, Howard GA, Roos BA, Schiller PC: Low oxygen tension inhibits osteogenic differentiation and enhances stemness of human MIAMI cells. Bone. 2006, 39: 513-22. 10.1016/j.bone.2006.02.061.View ArticlePubMed
- Lord-Dufour S, Copland IB, Levros LC, Post M, Das A, Khosla C, Galipeau J, Rassart E, Annabi B: Evidence for Transcriptional Regulation of the Glucose-6-Phosphate Transporter by HIF-1a: Targeting G6PT with Mumbaistatin Analogs in Hypoxic Mesenchymal Stromal Cells. Stem Cells. 2009, 27: 489-97. 10.1634/stemcells.2008-0855.PubMed CentralView ArticlePubMed
- Huang Y, Du KM, Xue ZH, Yan H, Li D, Liu W, Chen Z, Zhao Q, Tong JH, Zhu YS, Chen GQ: Cobalt chloride and low oxygen tension trigger differentiation of acute myeloid leukemic cells: possible mediation of hypoxia-inducible factor-1alpha. Leukemia. 2003, 17: 2065-73. 10.1038/sj.leu.2403141.View ArticlePubMed
- Hirsilä M, Koivunen P, Xu L, Seeley T, Kivirikko KI, Myllyharju J: Effect of desferrioxamine and metals on the hydroxylases in the oxygen sensing pathway. FASEB J. 2005, 19: 1308-10.PubMed
- Jung JY, Kim WJ: Involvement of mitochondrial- and Fas-mediated dual mechanism in CoCl2-induced apoptosis of rat PC12 cells. Neurosci Lett. 2004, 23: 85-90.View Article
- An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM: Stabilization of wild-type p53 by hypoxia-inducible factor 1 α. Nature. 1998, 392: 405-8. 10.1038/32925.View ArticlePubMed
- He MC, Li J, Zhao CH: Effect of hypoxia on mesenchymal stem cells - review. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007, 15: 433-6.PubMed
- Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E: Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006, 8: 315-7. 10.1080/14653240600855905.View ArticlePubMed
- Hayakawa K, Sato N, Obinata T: Dynamic reorientation of cultured cells and stress fibers under mechanical stress from periodic stretching. Exp Cell Res. 2001, 268: 104-14. 10.1006/excr.2001.5270.View ArticlePubMed
- Danti S, D'Acunto M, Trombi L, Berrettini S, Pietrabissa A: A micro/nanoscale surface mechanical study on morpho-functional changes in multilineage-differentiated human mesenchymal stem cells. Macromol Biosci. 2007, 7: 589-98. 10.1002/mabi.200600271.View ArticlePubMed
- Qu ZH, Zhang XL, Tang TT, Dai KR: Promotion of osteogenesis through b-catenin signaling by desferrioxaminutes. Biochem Biophys Res Comm. 2008, 370: 332-37. 10.1016/j.bbrc.2008.03.092.View ArticlePubMed
- Valorani MG, Germani A, Otto WR, Harper L, Biddle A, Khoo CP, Lin WR, Hawa MI, Tropel P, Patrizi MP, Pozzilli P, Alison MR: Hypoxia increases Sca-1/CD44 co-expression in murine mesenchymal stem cells and enhances their adipogenic differentiation potential. Cell Tissue Res. 2010, 341: 111-20. 10.1007/s00441-010-0982-8.View ArticlePubMed
- Ma T, Grayson WL, Fröhlich M, Vunjak-Novakovic G: Hypoxia and Stem Cell-Based Engineering of Mesenchymal Tissues. Biotechnol Prog. 2009, 25: 32-42. 10.1002/btpr.128.PubMed CentralView ArticlePubMed
- Richardson SM, Hoyland JA, Mobasheri R, Csaki C, Shakibaei M, Mobasheri A: Mesenchymal stem cells in regenerative medicine: opportunities and challenges for articular cartilage and intervertebral disc tissue engineering. J Cell Physiol. 2010, 222: 23-32. 10.1002/jcp.21915.View ArticlePubMed
- Wang D, Shen W, Zhang F, Chen M, Chen H, Cao K: Connexin43 promotes survival of mesenchymal stem cells in ischemic heart. Cell Biol Int. 2010, 34: 415-23. 10.1042/CBI20090118.View ArticlePubMed
- Liu H, Xue W, Ge G, Luo X, Li Y, Xiang H, Ding X, Tian P, Tian X: Hypoxic preconditioning advances CXCR4 and CXCR7 expression by activating HIF-1alpha in MSCs. Biochem Biophys Res Commun. 2010, 401: 509-15. 10.1016/j.bbrc.2010.09.076.View ArticlePubMed
- Lavrentieva A, Majore I, Kasper C, Hass R: Effects of hypoxic culture conditions on umbilical cord-derived human mesenchymal stem cells. Cell Commun Signal. 2010, 8: 18-10.1186/1478-811X-8-18.PubMed CentralView ArticlePubMed
- Holzwarth C, Vaegler M, Gieseke F, Pfister SM, Handgretinger R, Kerst G, Müller I: Low physiologic oxygen tensions reduce proliferation and differentiation of human multipotent mesenchymal stromal cells. BMC Cell Biol. 2010, 11: 11-10.1186/1471-2121-11-11.PubMed CentralView ArticlePubMed
- Pacary E, Legros H, Valable S, Duchatelle P, Lecocq M, Petit E, Nicole O, Bernaudin M: Synergistic effects of CoCl(2) and ROCK inhibition on mesenchymal stem cell differentiation into neuron-like cells. J Cell Sci. 2006, 119: 2667-78. 10.1242/jcs.03004.View ArticlePubMed
- Bruder SP, Jaiswal N, Haynesworth SE: Growth kinetics, selfrenewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J Cell Biochem. 1997, 64: 278-94. 10.1002/(SICI)1097-4644(199702)64:2<278::AID-JCB11>3.0.CO;2-F.View ArticlePubMed
- Shav-Tal Y, Lee BC, Bar-Haim S, Schori H, Zipori D: Reorganization of nuclear factors during myeloid differentiation. J Cell Biochem. 2001, 81: 379-92. 10.1002/1097-4644(20010601)81:3<379::AID-JCB1052>3.0.CO;2-8.View ArticlePubMed
- Wiblin AE, Cui W, Clark AJ, Bickmore WA: Distinctive nuclear organisation of centromeres and regions involved in pluripotency in human embryonic stem cells. J Cell Sci. 2005, 118: 3861-8. 10.1242/jcs.02500.View ArticlePubMed
- Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser JK, Benhaim P, Hedrick MH: Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2002, 13: 4279-95. 10.1091/mbc.E02-02-0105.PubMed CentralView ArticlePubMed
- Karahuseyinoglu S, Cinar O, Kilic E, Kara F, Akay GG, Demiralp DO, Tukun A, Uckan D, Can A: Biology of the stem cells in human umbilical cord stroma: In situ and in vitro surveys. Stem cells. 2007, 25: 319-31. 10.1634/stemcells.2006-0286.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.